Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 13/20 | 0.62 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.51 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.51 |
| ▸ | BRD4 | O60885 | 3/20 | 0.49 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.49 |
| ▸ | TAF1 | P21675 | 2/20 | 0.49 |
| ▸ | STK4 | Q13043 | 4/20 | 0.47 |
| ▸ | MARK3 | P27448 | 1/20 | 0.45 |
| ▸ | TTK | P33981 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1202832 | 0.90 | PLK1 (0.63) | PLK1MAPK7DYRK1ABRD4BRDT | |
| SCHEMBL1559081 | 0.89 | PLK1 (0.77) | PLK1MAPK7DYRK1ABRD4BRDT | |
| SCHEMBL1560424 | 0.89 | PLK1 (0.75) | PLK1MAPK7DYRK1ABRD4BRDT | |
| SCHEMBL1559047 | 0.88 | PLK1 (0.74) | PLK1MAPK7DYRK1ABRD4BRDT | |
| SCHEMBL4078274 | 0.87 | PLK1 (0.55) | PLK1BRD4BRDTTTK | |
| SCHEMBL3671781 | 0.87 | PLK1 (0.83) | PLK1BRD4BRDTTAF1 | |
| SCHEMBL1202528 | 0.87 | PLK1 (0.56) | PLK1BRD4BRDTTTK | |
| SCHEMBL12880277 | 0.87 | PLK1 (0.56) | PLK1BRD4BRDT | |
| SCHEMBL3666936 | 0.86 | PLK1 (0.70) | PLK1BRD4BRDTTAF1 | |
| SCHEMBL1203728 | 0.86 | PLK1 (0.68) | PLK1BRD4BRDTTTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9493471-B2 | Pyrimidine derivatives as protein kinase inhibitors | CYCLACEL LIMITED (GB) | 2016-11-15 | — | — | US | disclosed |
| US-9493471-B2 | Pyrimidine derivatives as protein kinase inhibitors | CYCLACEL LIMITED (GB) | 2016-11-15 | — | — | US | disclosed |
| US-20150344486-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2015-12-03 | — | — | US | disclosed |
| US-20150344486-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2015-12-03 | — | — | US | disclosed |
| US-9133199-B2 | Pyrimidine derivatives as protein kinase inhibitors | CYCLACEL LIMITED (GB) | 2015-09-15 | — | — | US | disclosed |
| US-9133199-B2 | Pyrimidine derivatives as protein kinase inhibitors | CYCLACEL LIMITED (GB) | 2015-09-15 | — | — | US | disclosed |
| US-20140066436-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | TETHRA BIOSCIENCES INC. | 2014-03-06 | — | — | US | disclosed |
| US-20140066436-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | TETHRA BIOSCIENCES INC. | 2014-03-06 | — | — | US | disclosed |
| US-8563542-B2 | Pyrimidine derivatives as protein kinase inhibitors | CYCLACEL LIMITED (GB) | 2013-10-22 | — | — | US | disclosed |
| US-8563542-B2 | Pyrimidine derivatives as protein kinase inhibitors | CYCLACEL LIMITED (GB) | 2013-10-22 | — | — | US | disclosed |
| US-20110046093-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2011-02-24 | — | — | US | disclosed |
| US-20110046093-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2011-02-24 | — | — | US | disclosed |
| EP-2139892-A1 | SUBSTITUTED PYRIMIDODIAZEPINES USEFUL AS PLK1 INHIBITORS | F. Hoffmann-Roche AG (CH) | 2010-01-06 | — | — | EP | disclosed |
| US-7517873-B2 | Substituted pyrimidodiazepines | HOFFMAN-LA ROCHE INC. (US) | 2009-04-14 | — | — | US | disclosed |
| WO-2008113711-A1 | SUBSTITUTED PYRIMIDODIAZEPINES USEFUL AS PLK1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-09-25 | — | — | WO | disclosed |
| US-20080234255-A1 | SUBSTITUTED PYRIMIDODIAZEPINES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234255-A1 | SUBSTITUTED PYRIMIDODIAZEPINES | PLK1, CCNI, CDK1 | PLK1 1/4885MAPK7 1466/4885DYRK1A 1262/4885 |
| US-20110046093-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CDK7, CDK9, CDK8 | PLK1 355/4885MAPK7 4/4885DYRK1A 1098/4885 |
| US-20140066436-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CDK7, CDK9, CDK8 | PLK1 349/4885MAPK7 4/4885DYRK1A 1047/4885 |
| US-20150344486-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | DCK, DTYMK, TK1 | PLK1 23/4885MAPK7 295/4885DYRK1A 697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.